论文部分内容阅读
目的 研究呼吸系统疾病患者血清GLS含量及其可能的临床意义。方法 用本作者建立的“GLS快速测定法”测定患者血清GLS ,分组统计分析。结果 血清GLS正常范围 2 72～ 6 6 0mgL-1( X± 2 .98SD)。肺癌组GLS90 8±2 89,阳性 (>6 6 0 )率 87.4 % ,十分显著高于其余各组 (P <0 .0 0 1) ;且低分化癌 >鳞癌 >腺癌 ,与恶性程度呈正相关。结核组GLS72 2± 2 94 ;4 2 .4 %阳性 ,主要为合并胸膜、胸椎结核或其他感染者。肺炎组GLS798± 2 89;6 2 .6 %阳性 ,主要为胸膜炎肺脓疡或伴纤维化者。慢支炎组GLS 6 30± 175 ;33.9%阳性 ,主要为急发期患者。“其他”组GLS5 31±82 ,阳性率仅 8.3%。结论 肺癌患者血清GLS显著增加 ;测定GLS对肺癌诊断可能有一定参考意义
Objective To study the serum GLS level in patients with respiratory diseases and its possible clinical significance. Methods Using the “GLS rapid determination method” established by this author, the serum GLS of patients was measured and the data were analyzed by grouping. Results Serum GLS normal range 2 72 ~ 6 6mgL-1 (X ± 2.98SD). Lung cancer group GLS90 8 ± 2 89, positive (> 6 6 0) rate of 87.4%, was significantly higher than the remaining groups (P <0.01); and poorly differentiated carcinoma> squamous cell carcinoma> adenocarcinoma, and malignancy Was positively correlated. Tuberculosis group GLS72 2 ± 2 94; 42.4% positive, mainly for the merger of the pleural, thoracic tuberculosis or other infections. Pneumonia group GLS798 ± 2 89; 62.6% positive, mainly pleurisy lung abscess or fibrosis. Chronic bronchitis group GLS 6 30 ± 175; 33.9% positive, mainly in patients with acute phase. “Other” group GLS5 31 ± 82, the positive rate of only 8.3%. Conclusion Serum GLS in patients with lung cancer significantly increased; GLS may have some reference value for the diagnosis of lung cancer